1
|
Pietro CD, Öz H, Zhang P, Cheng E, Martis V, Bonfield T, Kelley T, Jubin R, Abuchowski A, Krause D, Egan M, Murray T, Bruscia E. 558: Carbon monoxide–based therapy primes macrophages to express HO-1 and to resolve lung hyper-inflammation in cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01981-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
2
|
Gerlich C, Andreica I, Küffner R, Krause D, Lakomek HJ, Reusch A, Braun J. Erratum zu: Evaluation einer Basisschulung für Patienten mit rheumatoider Arthritis. Z Rheumatol 2021:10.1007/s00393-021-01049-5. [PMID: 34241693 DOI: 10.1007/s00393-021-01049-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- C Gerlich
- Arbeitsbereich Medizinische Psychologie und Psychotherapie im Zentrum für psychische Gesundheit (ZEP), Universität Würzburg, Klinikstr. 3, 97070, Würzburg, Deutschland.
| | - I Andreica
- Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Deutschland
| | - R Küffner
- Arbeitsbereich Medizinische Psychologie und Psychotherapie im Zentrum für psychische Gesundheit (ZEP), Universität Würzburg, Klinikstr. 3, 97070, Würzburg, Deutschland
| | - D Krause
- Praxis Innere Medizin/Rheumatologie, Gladbeck, Deutschland
| | - H J Lakomek
- Klinik für Rheumatologie und Geriatrie, Johannes Wesling Klinikum Minden, Minden, Deutschland
| | - A Reusch
- Zentrum Patientenschulung und Gesundheitsförderung, Würzburg, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Deutschland
| |
Collapse
|
3
|
Kiltz U, Andreica I, Igelmann M, Kalthoff L, Krause D, Schmitz E, McKenna SP, Braun J. [Standardized documentation of health-related quality of life in patients with psoriatic arthritis : Validation of the German version of the psoriatic arthritis quality of life (PsAQoL) questionnaire]. Z Rheumatol 2021; 80:122-131. [PMID: 32748078 PMCID: PMC7929954 DOI: 10.1007/s00393-020-00843-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND The standardized assessment of health-related quality of life is becoming increasingly more important. The English questionnaire on psoriatic arthritis quality of life (PsAQoL) is a disease-specific instrument for measuring the quality of life of patients with psoriatic arthritis (PsA). The aim of the present study was to translate the PsAQoL into German and to validate the German version in a cohort of PsA patients recruited from routine care. METHOD The translation and validation of the PsAQoL questionnaire was carried out in a stepwise procedure involving affected patients with PsA. After translation of the original English questionnaire the German version was evaluated in a field test. The psychometric features of the questionnaire were then examined in a PsA cohort from routine care. In addition to the construct and group validity, the reliability of the questionnaire was tested using test-retest reliability and internal consistency. The physical functioning was measured with the health assessment questionnaire (HAQ) and domains of the quality of life with the Nottingham health profile (NHP). RESULTS In a field test with 10 patients the German version of the PsAQoL questionnaire proved to be relevant, easily understandable and feasible (processing time 4.7 ± 2.1 min). A total of 126 patients (37.3% male, age 55.6 ± 11.3 years) were included in the validation cohort. The PsAQoL showed moderate correlation with the HAQ (r = 0.65) and moderate to good correlation with the NHP (subdomains r = 0.58-0.75). The internal consistency was high (Cronbach's α 0.92) and reliability in patients with stable disease course was very good (Spearman correlation coefficient 0.94). The PsAQoL can differentiate between different patient groups. CONCLUSION The German translation of the PsAQoL provides a valid disease-specific instrument for the standardized assessment of health-related quality of life in patients with PsA. The psychometric characteristics of this questionnaire are comparable with the original English version. The German PsAQoL can therefore be recommended for clinical and scientific application.
Collapse
Affiliation(s)
- U Kiltz
- Rheumazentrum Ruhrgebiet, Herne und Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland.
| | - I Andreica
- Rheumazentrum Ruhrgebiet, Herne und Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland
| | - M Igelmann
- Praxis für Rheumatologie, Bochum, Deutschland
| | - L Kalthoff
- Privatärztliche Praxis für Immunologie, Rheumatologie, Osteologie, Bochum, Deutschland
| | - D Krause
- Rheumatologische Gemeinschaftspraxis, Gladbeck, Deutschland
| | - E Schmitz
- Praxis für Rheumatologie, Hattingen, Deutschland
| | - S P McKenna
- Galen Research Ltd. Manchester, Manchester, Vereinigtes Königreich
| | - J Braun
- Rheumazentrum Ruhrgebiet, Herne und Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland
| |
Collapse
|
4
|
Hirsch M, San Martin M, Krause D. Neuropathic osteoarthropathy of the shoulder secondary to syringomyelia. Diagn Interv Imaging 2020; 102:193-194. [PMID: 33092999 DOI: 10.1016/j.diii.2020.09.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 09/18/2020] [Accepted: 09/21/2020] [Indexed: 11/24/2022]
Affiliation(s)
- M Hirsch
- Department of Radiology, Clínica Alemana de Temuco, Senador Estebanez #645, ZC: 4810552, Temuco, Chile; Department of Medical Specialties, Universidad de la Frontera, Claro Solar #115, ZC: 4781218, Temuco, Chile
| | - M San Martin
- Department of Radiology, Clínica Alemana de Temuco, Senador Estebanez #645, ZC: 4810552, Temuco, Chile; Department of Medical Specialties, Universidad de la Frontera, Claro Solar #115, ZC: 4781218, Temuco, Chile.
| | - D Krause
- Department of Medical Specialties, Universidad de la Frontera, Claro Solar #115, ZC: 4781218, Temuco, Chile
| |
Collapse
|
5
|
Lichter K, Krause D, Xu J, Hage C, Tsai L, Weston E, Eke A, Levinson K. Adjuvant HPV vaccination with surgical excision to prevent recurrent CIN2+: A systematic review and meta-analysis. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Mai A, Krause D, Braun J, Böddeker S, Braun J, Dybowski F, Fendler C, Günzel J, Hübner G, Krause D, Klink C, Lakomek HJ, Menne HJ, Raub W, Rittstieg A, Saracbasi-Zender E, Sarholz M, Scheibl G, Schmid A, Schmitz E, Schoo U, Sonntag M, Stein S, Trampisch HJ, Timmesfeld N, Mai A, Klaaßen-Mielke R, Reese JP, Dupuy Backofen C, Westerhoff B, Voormann AJ, Gromnica-Ihle E, Gursch A, Andreica I, Baraliakos X, Guminski B, Reichmuth G, Trampisch U. Ist eine Team-basierte rheumatologische Versorgung mit Delegation an die Fachassistenz der Standardversorgung ebenbürtig oder sogar überlegen? – Das StärkeR-Projekt. Z Rheumatol 2020; 79:52-54. [DOI: 10.1007/s00393-020-00864-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
7
|
Kiltz U, Andreica I, Igelmann M, Kalthoff L, Krause D, Schmitz E, McKenna SP, Braun J. [Erratum to: Standardized documentation of health-related quality of life in patients with psoriatic arthritis. Validation of the German version of the psoriatic arthritis quality of life (PsAQoL) questionnaire]. Z Rheumatol 2020; 80:131. [PMID: 32876873 DOI: 10.1007/s00393-020-00869-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- U Kiltz
- Rheumazentrum Ruhrgebiet, Herne und Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland.
| | - I Andreica
- Rheumazentrum Ruhrgebiet, Herne und Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland
| | - M Igelmann
- Praxis für Rheumatologie, Bochum, Deutschland
| | - L Kalthoff
- Privatärztliche Praxis für Immunologie, Rheumatologie, Osteologie, Bochum, Deutschland
| | - D Krause
- Rheumatologische Gemeinschaftspraxis, Gladbeck, Deutschland
| | - E Schmitz
- Praxis für Rheumatologie, Hattingen, Deutschland
| | - S P McKenna
- Galen Research Ltd. Manchester, Manchester, Großbritannien
| | - J Braun
- Rheumazentrum Ruhrgebiet, Herne und Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland
| |
Collapse
|
8
|
Janke K, Biester K, Krause D, Richter B, Schürmann C, Hirsch K, Wieseler B. THU0620-HPR MEASUREMENT OF LOW DISEASE ACTIVITY USING THE CLINICAL DISEASE ACTIVITY INDEX (CDAI) VERSUS THE DISEASE ACTIVITY SCORE 28 (DAS 28): IMPACT OF INFLAMMATION MARKERS ON THE COMPARATIVE EFFECTIVENESS OF BIOLOGICS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Biologics for the treatment of rheumatoid arthritis (RA) have different modes of action to target auto-inflammatory processes causing the signs and symptoms of the disease. Different biologics may thus have different effects on inflammatory markers. For instance, previous studies have shown that the interleukin-6-inhibitor tocilizumab (TOC) decreases the level of acute phase reactants (APRs) [1]. Such direct effects on inflammatory markers may lead to an overestimation of clinical response if disease activity is measured via scores including inflammatory markers, such as the Disease Activity Score 28 (DAS 28). The detected changes in disease activity may not adequately reflect the clinical improvement of signs and symptoms.Objectives:In our study, we compared biologics with each other using two different disease activity scores: the DAS 28 including APRs and the clinical disease activity index (CDAI) excluding APRs. The aim of this study was to assess whether the use of the two different scores affects comparative effectiveness studies on biologics for the treatment of RA.Methods:We compared results on the comparative effectiveness of biologics using the corresponding thresholds for low disease activity (LDA) for the DAS 28 (< 3.2) and the CDAI (≤ 10). We performed two separate network meta-analyses (NMAs) after a thorough step-by-step evaluation of the similarity, homogeneity and consistency assumptions of the patient populations and the study data.Our study formed part of a systematic review (including NMAs) that was largely based on clinical study reports and re-analyses of LDA using individual patient data provided by sponsors for studies conducted up to 2017. Thus, the analyses include hitherto unknown data on LDA analysed by means of the CDAI, especially data from older studies. An extensive comparison of DAS 28 and CDAI in different patient populations was possible.Results:For all analysed patient populations, comparisons of TOC versus other biologics yielded remarkable results: advantages for TOC were found in NMAs using the DAS 28, which were not confirmed in NMAs using the CDAI. For methotrexate (MTX)-naïve patients, using the DAS 28, TOC showed a greater benefit than abatacept (ABA), certolizumab pegol (CZP), and etanercept (ETA), which was not confirmed by the CDAI. In contrast, TOC showed less benefit than adalimumab (ADA) and ETA. For patients after MTX failure and using the DAS 28, TOC showed a greater benefit than ABA, ADA, anakinra (ANA), ETA, golimumab (GOL), and infliximab (INF). With the exception of ANA, these advantages were not confirmed by the CDAI. Similar differences between DAS 28 and CDAI were shown in patients treated with biologics in monotherapy or after failure of biologics.Conclusion:In comparative effectiveness studies of biologics, the assessment of LDA using the DAS 28 instead of the CDAI leads to a consistent overestimation of the benefit of TOC in all patient populations, regardless of pre-treatment or combined therapy with MTX. The inclusion of APRs in disease activity scores may thus introduce bias. A score excluding inflammatory markers should therefore be used to ensure valid results.References:[1]Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011; 63(1): 43-52.Disclosure of Interests:Kirsten Janke: None declared, Katharina Biester: None declared, Dietmar Krause Grant/research support from: Pfizer and AbbVie (Abbott), Bernd Richter: None declared, Christoph Schürmann: None declared, Katharina Hirsch: None declared, Beate Wieseler: None declared
Collapse
|
9
|
Krause D, Mai A, Timmesfeld N, Trampisch U, Klaassen-Mielke R, Rudolf H, Baraliakos X, Schmitz E, Fendler C, Klink C, Boeddeker S, Saracbasi E, Christoph J, Igelmann M, Menne HJ, Schmid A, Trampisch HJ, Braun J. SAT0135 COMPARISON OF THE EFFICACY AND SAFETY OF TWO BRIDGING SCHEDULES OF PREDNISOLONE IN EARLY ACTIVE RHEUMATOID ARTHRITIS (CORRA): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rheumatoid arthritis (RA) is a chronic inflammatory joint disease potentially leading to disability, impaired functioning, and premature death. Most treatment strategies include the early use of disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX) which is considered as an established ‘anchor’ therapy. Since it takes some weeks until MTX shows clinical efficacy, glucocorticoids (GC) are widely used for bridging.Objectives:The aim of the study “Comparison of the efficacy and safety of two starting dosages of prednisolone in early active RA” (CORRA) is to compare the efficacy and safety of two standard GC bridging schedules vs. placebo in addition to MTX, following a treat-to-target regimen, in early RA.Methods:CORRA is an investigator-initiated, randomised, multi-center, double-blind, placebo-controlled trial. Adult RA patients who were eligible for inclusion in the trial if they had a disease duration of less than 3 years and moderate or high disease activity were recruited in one hospital and 18 rheumatology practices in Germany. Patients were randomised (1:1:1) to receive 60 mg or 10 mg prednisolone (Pred) orally once daily (tapered down to 5 mg Pred within 8 weeks) or placebo. The duration of the intervention was 12 weeks, followed by an open observational phase for another 40 weeks. All patients were also treated with MTX (usually starting with 15mg/week followed by a treat-to target scheme). The primary efficacy endpoint was the progression of the radiographic joint damage after one year compared to baseline as determined by the van der Heijde modification of the Sharp score (SHS). Patients, physicians and readers of radiographs were unaware of the treatment assignments. For the comparison of the two GC groups, a non-inferiority margin of 1.3 points of the SHS was set. This trial was registered at ClinicalTrials.gov, numberNCT02000336.Results:Between February 2014 and February 2017, 395 patients were included in the trial, 381 of which had sufficient data also of follow-up visits. A total of 129 patients were assigned to the 60 mg Pred group, 124 to 10 mg Pred and 128 to the placebo group. At baseline, mean age was 58 years, 58% were female, 55% were rheumatoid factor and 52% ACPA positive. The mean number of swollen joints was 12.8 out of 28, mean ESR was 33.6 mm/h, mean CRP 2.2 mg/dL, mean DAS 28 6.0. Radiographic damage was 4.9 as measured by the SHS. In the 60 mg, 10 mg Pred group and in the placebo group, the DAS 28 was 2.6, 3.1, 4.5 at week 4 (p<0.001), 3.1, 2.8, 3.6 at week 12 (p<0.001), and 2.7, 2.6, 2.8 at week 52 (p=0.411), respectively. After 12 months the radiographic progression could be determined in 375 patients. In the 60 mg, 10 mg Pred group, and in the placebo group, the mean progression after 1 year was 1.0, 1.0, 1.1 for the total SHS and 0.5, 0.6, 0.7 for the erosion score of the SHS, respectively. Statistical analysis showed non-inferiority of the 10 mg Pred and of the placebo group in comparison to the 60 mg Pred group. Regarding safety issues, there were 10, 5, 6 serious adverse events and 31, 16, 20 adverse events in the MedDRA system organ class “infections and infestations” for the 60 mg Pred, 10 mg Pred, and the placebo group, respectively.Conclusion:The bridging schedule starting with 60 mg Pred reduced disease activity better than the 10 mg schedule or placebo only for a short time. The primary outcome structural damage was non-inferior in the 10 mg Pred and the placebo group in comparison to the 60 mg Pred group. Initial advantages of the higher dose may have been compromised by the long follow-up with the possible escalation of therapy due to the treat-to-target regimen.Disclosure of Interests:Dietmar Krause Grant/research support from: Pfizer and AbbVie (Abbott), Anna Mai: None declared, Nina Timmesfeld: None declared, Ulrike Trampisch: None declared, Renate Klaassen-Mielke: None declared, Henrik Rudolf: None declared, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Elmar Schmitz: None declared, Claas Fendler: None declared, Claudia Klink: None declared, Stephanie Boeddeker: None declared, Ertan Saracbasi: None declared, Jochen Christoph: None declared, Manfred Igelmann: None declared, Hans Juergen Menne: None declared, Albert Schmid: None declared, Hans J Trampisch: None declared, Juergen Braun Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Eli Lilly and Company, Medac, MSD (Schering Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi- Aventis, and UCB Pharma, Consultant of: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Speakers bureau: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma
Collapse
|
10
|
Kiltz U, Braun J, Becker A, Chenot JF, Dreimann M, Hammel L, Heiligenhaus A, Hermann KG, Klett R, Krause D, Kreitner KF, Lange U, Lauterbach A, Mau W, Mössner R, Oberschelp U, Philipp S, Pleyer U, Rudwaleit M, Schneider E, Schulte TL, Sieper J, Stallmach A, Swoboda B, Winking M. [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations]. Z Rheumatol 2020; 78:3-64. [PMID: 31784900 DOI: 10.1007/s00393-019-0670-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- U Kiltz
- Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland.
| | - J Braun
- Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland
| | | | - A Becker
- Allgemeinmedizin, präventive und rehabilitative Medizin, Universität Marburg, Karl-von-Frisch-Str. 4, 35032, Marburg, Deutschland
| | | | - J-F Chenot
- Universitätsmedizin Greifswald, Fleischmann Str. 6, 17485, Greifswald, Deutschland
| | - M Dreimann
- Zentrum für Operative Medizin, Klinik und Poliklinik für Unfall‑, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Hamburg-Eppendorf (UKE), Martinistraße 52, 20251, Hamburg, Deutschland
| | | | - L Hammel
- Geschäftsstelle des Bundesverbandes der DVMB, Metzgergasse 16, 97421, Schweinfurt, Deutschland
| | | | - A Heiligenhaus
- Augenzentrum und Uveitis-Zentrum, St. Franziskus Hospital, Hohenzollernring 74, 48145, Münster, Deutschland
| | | | - K-G Hermann
- Institut für Radiologie, Charité Berlin, Charitéplatz 1, 10117, Berlin, Deutschland
| | | | - R Klett
- Praxis Manuelle & Osteopathische Medizin, Fichtenweg 17, 35428, Langgöns, Deutschland
| | | | - D Krause
- , Friedrich-Ebert-Str. 2, 45964, Gladbeck, Deutschland
| | - K-F Kreitner
- Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland
| | - U Lange
- Kerckhoff-Klinik, Rheumazentrum, Osteologie & Physikalische Medizin, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland
| | | | - A Lauterbach
- Schule für Physiotherapie, Orthopädische Universitätsklinik Friedrichsheim, Marienburgstraße 2, 60528, Frankfurt, Deutschland
| | | | - W Mau
- Institut für Rehabilitationsmedizin, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, 06097, Halle (Saale), Deutschland
| | - R Mössner
- Klinik für Dermatologie, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland
| | | | - U Oberschelp
- , Barlachstr. 6, 59368, Werne a.d. L., Deutschland
| | | | - S Philipp
- Praxis für Dermatologie, Bernauer Str. 66, 16515, Oranienburg, Deutschland
| | - U Pleyer
- Campus Virchow-Klinikum, Charité Centrum 16, Klinik f. Augenheilkunde, Charité, Augustenburger Platz 1, 13353, Berlin, Deutschland
| | - M Rudwaleit
- Klinikum Bielefeld, An der Rosenhöhe 27, 33647, Bielefeld, Deutschland
| | - E Schneider
- Abt. Fachübergreifende Frührehabilitation und Sportmedizin, St. Antonius Hospital, Dechant-Deckersstr. 8, 52249, Eschweiler, Deutschland
| | - T L Schulte
- Klinik für Orthopädie und Unfallchirurgie, Orthopädische Universitätsklinik, Ruhr-Universität Bochum, Gudrunstr. 65, 44791, Bochum, Deutschland
| | - J Sieper
- Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland
| | - A Stallmach
- Klinik für Innere Medizin IV, Universitätsklinikum Jena, Am Klinikum 1, 07743, Jena, Deutschland
| | | | - B Swoboda
- Abteilung für Orthopädie und Rheumatologie, Orthopädische Universitätsklinik, Malteser Waldkrankenhaus St. Marien, 91054, Erlangen, Deutschland
| | | | - M Winking
- Zentrum für Wirbelsäulenchirurgie, Klinikum Osnabrück, Am Finkenhügel 3, 49076, Osnabrück, Deutschland
| | | |
Collapse
|
11
|
Holtz C, Krause D, Hussein M, Gastl M, Becker T. Lautering Performance Prediction from Malt by Combining Whole Near-Infrared Spectral Information with Lautering Process Evaluation as Reference Values. Journal of the American Society of Brewing Chemists 2018. [DOI: 10.1094/asbcj-2014-0717-01] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- C. Holtz
- Lehrstuhl für Brau- und Getränketechnologie, Technische Universität München, Weihenstephan, Weihenstephaner Steig 20, 85354 Freising, Germany
| | - D. Krause
- Lehrstuhl für Brau- und Getränketechnologie, Technische Universität München, Weihenstephan, Weihenstephaner Steig 20, 85354 Freising, Germany
| | - M. Hussein
- Lehrstuhl für Brau- und Getränketechnologie, Technische Universität München, Weihenstephan, Weihenstephaner Steig 20, 85354 Freising, Germany
| | - M. Gastl
- Lehrstuhl für Brau- und Getränketechnologie, Technische Universität München, Weihenstephan, Weihenstephaner Steig 20, 85354 Freising, Germany
| | - T. Becker
- Lehrstuhl für Brau- und Getränketechnologie, Technische Universität München, Weihenstephan, Weihenstephaner Steig 20, 85354 Freising, Germany
| |
Collapse
|
12
|
Zink A, Braun J, Gromnica-Ihle E, Krause D, Lakomek HJ, Mau W, Müller-Ladner U, Rautenstrauch J, Specker C, Schneider M. [Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology - Update 2016]. Z Rheumatol 2017; 76:195-207. [PMID: 28364218 DOI: 10.1007/s00393-017-0297-1] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
On behalf of the Steering Committee of the German Society for Rheumatology, in 2016 the Interdisciplinary Commission on Healthcare Quality updated the 2008 memorandum on rheumatological healthcare in Germany. The update considers changes in therapeutic strategies, treatment targets as well as current structures in healthcare and the political framework. It concentrates on examination of the need for rheumatologists with a background in internal medicine and determines the gap between needs and supply. The internist rheumatologist is responsible for the care of patients with inflammatory rheumatic diseases and contributes to the care of patients with severe forms of other musculoskeletal diseases. At least 2 internist rheumatologists are needed for the outpatient care of 100,000 adult inhabitants, equivalent to 1350 rheumatologists in Germany. With currently 776 rheumatologists, we have little more than half of what we need. The German Society for Rheumatology calls for specific requirements planning for rheumatologists in outpatient care in order to decrease the deficit. In acute inpatient care we need specialized hospitals and wards that ensure a high quality of treatment for patients with complex diseases. We need up to 50 beds per 1 million inhabitants. At least 2 full-time internist rheumatologists and 3 further physicians are needed per 30 beds. In inpatient and outpatient rehabilitation we need 40 beds or outpatient places per 1 million inhabitants with at least 1 full-time rheumatologist and 1 further physician. In order to reduce the existing deficits and to cover the increasing future need for rheumatologists, more emphasis has to be laid on primary and secondary education. Chairs for internal rheumatology are needed at each medical university and more positions for postgraduate training in rheumatology should be provided. In all segments of healthcare the treatment aims should be jointly defined between patients and physicians. The patients should be treated in an interdisciplinary network, comprising other medical specialties, health professionals as well as patient organizations.
Collapse
Affiliation(s)
- A Zink
- Deutsches Rheuma-Forschungszentrum Berlin, Programmbereich Epidemiologie und Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
| | - J Braun
- Rheumazentrum Ruhrgebiet, Herne, Deutschland
| | | | - D Krause
- Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Deutschland
| | - H J Lakomek
- Klinik für Rheumatologie und Interdisziplinäre Geriatrie, Universitätszentrum Innere Medizin, Johannes Wesling Klinikum Minden, Minden, Deutschland
| | - W Mau
- Institut für Rehabilitationsmedizin, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland
| | - U Müller-Ladner
- Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie, Justus-Liebig-Universität Gießen, Gießen, Deutschland
- Abteilung Rheumatologie und klinische Immunologie, Kerckhoff-Klinik GmbH, Bad Nauheim, Deutschland
| | - J Rautenstrauch
- Deutsche Gesellschaft für Rheumatologie, Berlin, Deutschland
| | - C Specker
- Klinik für Rheumatologie & Klinische Immunologie, Rheumazentrum Rhein-Ruhr e.V., St. Josef Krankenhaus (Universitätsklinikum Essen), Essen, Deutschland
| | - M Schneider
- Poliklinik und Funktionsbereich für Rheumatologie, Hiller Forschungszentrum Rheumatologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| |
Collapse
|
13
|
|
14
|
Jacquier M, Samson M, Audia S, Leguy-Seguin V, Berthier S, Nicolas B, Falvo N, Guilhem A, Krause D, Loffroy R, Steinmetz E, Bonnotte B. Dissection aortique traitée par corticothérapie. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Frölich AMJ, Spallek J, Brehmer L, Buhk JH, Krause D, Fiehler J, Kemmling A. 3D Printing of Intracranial Aneurysms Using Fused Deposition Modeling Offers Highly Accurate Replications. AJNR Am J Neuroradiol 2016; 37:120-4. [PMID: 26294648 DOI: 10.3174/ajnr.a4486] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 06/17/2015] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE As part of a multicenter cooperation (Aneurysm-Like Synthetic bodies for Testing Endovascular devices in 3D Reality) with focus on implementation of additive manufacturing in neuroradiologic practice, we systematically assessed the technical feasibility and accuracy of several additive manufacturing techniques. We evaluated the method of fused deposition modeling for the production of aneurysm models replicating patient-specific anatomy. MATERIALS AND METHODS 3D rotational angiographic data from 10 aneurysms were processed to obtain volumetric models suitable for fused deposition modeling. A hollow aneurysm model with connectors for silicone tubes was fabricated by using acrylonitrile butadiene styrene. Support material was dissolved, and surfaces were finished by using NanoSeal. The resulting models were filled with iodinated contrast media. 3D rotational angiography of the models was acquired, and aneurysm geometry was compared with the original patient data. RESULTS Reproduction of hollow aneurysm models was technically feasible in 8 of 10 cases, with aneurysm sizes ranging from 41 to 2928 mm(3) (aneurysm diameter, 3-19 mm). A high level of anatomic accuracy was observed, with a mean Dice index of 93.6% ± 2.4%. Obstructions were encountered in vessel segments of <1 mm. CONCLUSIONS Fused deposition modeling is a promising technique, which allows rapid and precise replication of cerebral aneurysms. The porosity of the models can be overcome by surface finishing. Models produced with fused deposition modeling may serve as educational and research tools and could be used to individualize treatment planning.
Collapse
Affiliation(s)
- A M J Frölich
- From the Department of Diagnostic and Interventional Neuroradiology (A.M.J.F., L.B., J.-H.B., J.F., A.K.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Spallek
- Technical University Hamburg-Harburg (D.K., J.S.), Institute of Product Development and Mechanical Engineering Design, Hamburg, Germany
| | - L Brehmer
- From the Department of Diagnostic and Interventional Neuroradiology (A.M.J.F., L.B., J.-H.B., J.F., A.K.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J-H Buhk
- From the Department of Diagnostic and Interventional Neuroradiology (A.M.J.F., L.B., J.-H.B., J.F., A.K.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Krause
- Technical University Hamburg-Harburg (D.K., J.S.), Institute of Product Development and Mechanical Engineering Design, Hamburg, Germany
| | - J Fiehler
- From the Department of Diagnostic and Interventional Neuroradiology (A.M.J.F., L.B., J.-H.B., J.F., A.K.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Kemmling
- From the Department of Diagnostic and Interventional Neuroradiology (A.M.J.F., L.B., J.-H.B., J.F., A.K.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
16
|
Abstract
OBJECTIVES The objective of this review was to evaluate the evidence from human studies on the intake of vitamins, either as monotherapies or in combination with other vitamins, as neuroprotective agents that may delay the onset of cognitive decline in older adults. METHODS Evidence-based methodologies were used to capture and evaluate the highest levels of evidence. FINDINGS The current evidence available showed no association for cognitive benefits of vitamins B6 or B12 as a monotherapy, and recent systematic reviews provide no clear evidence that supplementation with vitamin B6, B12 and/or folic acid improves dementia outcomes or slows cognitive decline, even though it may normalise homocysteine levels. Meta-analyses from systematic reviews have shown an association between low vitamin D levels and diminished cognitive function, although causality cannot be confirmed from the available evidence. There is no convincing evidence for an association of vitamin A, vitamin C or vitamin E either as a monotherapy or in combination with other antioxidant vitamins such as β-carotene and the prevention of cognitive decline. The appraisal of nineteen systematic reviews and meta-analyses has highlighted the heterogeneity between studies, and the need for better consensus on definitions of cognitive decline, duration of testing and agreement on which specific endpoints are clinically relevant. CONCLUSIONS Evaluation of the totality of the currently available evidence indicates that intake of the above vitamins, either as a monotherapy, or in combination with other vitamins, has no clinically-relevant effect on delaying cognitive decline or delaying the onset of dementia in older adults.
Collapse
Affiliation(s)
- D Krause
- Debra Krause, CSIRO Food and Nutrition Flagship, Private Bag 16, 671 Sneydes Road, Werribee 3030, Victoria, Australia, E-mail: , Telephone: +61 3 9731 3280, Fax: +61 3 9731 3201
| | | |
Collapse
|
17
|
Baraliakos X, Regel A, Kiltz U, Kiefer D, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause D, Saracbasi E, Schmitz-Bortz E, Braun J. OP0038 Patients with Fibromyalgia (FM) do not Fulfill Classification Criteria for Axial Spondyloarthritis (AXSPA) but Patients with Axspa May Fulfill Classification Criteria for FM. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5965] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Kiltz U, von Zabern C, Baraliakos X, Heldmann F, Mintrop B, Andreica I, Sarholz M, van Werde M, Klink C, Krause D, Dybowski F, Kalthoff L, Hein L, Braun J. FRI0608 Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis: Table 1. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
19
|
Schmitz-Bortz E, Baraliakos X, Braun J, Arndt S, Christoph J, Dybowski F, Hein L, Hübner G, Igelmann M, Kalthoff L, Klinik C, Menne J, Mintrop B, Schmid A, Schoo U, Krause D. AB0450 Outpatients' Biologic Agent Therapy in Private Practices in Western Germany – a Survey and a Retrospective Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
20
|
Krause D. 3D-Druck in der Medizin: Einführung und Anwendungsmöglichkeiten am Beispiel der Entwicklung von Aneurysmamodellen. ROFO-FORTSCHR RONTG 2015. [DOI: 10.1055/s-0035-1550811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Boyer P, Kehrli P, Buchheit F, Srour R, Albuquerque AMD, Krause D, Maitrot D. Intracavernous Epidermoid Tumor. Skull Base Surg 2015. [DOI: 10.1159/000429894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
22
|
Schaal T, Kummer A, Krause D. Gesundheitsförderung in der stationären Altenpflege – ein Ansatz zur Erhöhung der Mitarbeitermotivation und Senkung der Arbeitsbelastung. Gesundheitswesen 2014. [DOI: 10.1055/s-0034-1387004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
23
|
Kiltz U, Rudwaleit M, Sieper J, Krause D, Chenot JF, Stallmach A, Jaresch S, Oberschelp U, Schneider E, Swoboda B, Böhm H, Heiligenhaus A, Pleyer U, Böhncke WH, Stemmer M, Braun J. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]. Z Rheumatol 2014; 73 Suppl 2:28-39. [PMID: 25181971 DOI: 10.1007/s00393-014-1428-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- U Kiltz
- Deutsche Gesellschaft für Rheumatologie (DGRh), -, -,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Kiltz U, Sieper J, Kellner H, Krause D, Rudwaleit M, Chenot JF, Stallmach A, Jaresch S, Braun J. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. Z Rheumatol 2014; 73 Suppl 2:78-96. [PMID: 25181978 DOI: 10.1007/s00393-014-1443-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- U Kiltz
- Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Deutschland,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Böhle E, Böhm H, Böhncke WH, Chenot JF, Heiligenhaus A, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschläger U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy]. Z Rheumatol 2014; 73 Suppl 2:69-70. [PMID: 25181976 DOI: 10.1007/s00393-014-1433-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- U Kiltz
- Deutsche Gesellschaft für Rheumatologie (DGRh), -, -,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Böhle E, Böhm H, Böhncke WH, Chenot JF, Heiligenhaus A, Hermann KG, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschläger U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 1 Introduction/preliminary comments]. Z Rheumatol 2014; 73 Suppl 2:23-5. [PMID: 25181969 DOI: 10.1007/s00393-014-1426-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- U Kiltz
- Deutsche Gesellschaft für Rheumatologie (DGRh), -, -,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Böhle E, Böhm H, Böhncke WH, Chenot JF, Heiligenhaus A, Hermann KG, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschläger U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen. Z Rheumatol 2014; 73 Suppl 2:26-7. [DOI: 10.1007/s00393-014-1427-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
28
|
Krause D, Hussein WB, Hussein MA, Becker T. Ultrasonic sensor for predicting sugar concentration using multivariate calibration. Ultrasonics 2014; 54:1703-1712. [PMID: 24679511 DOI: 10.1016/j.ultras.2014.02.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Revised: 02/10/2014] [Accepted: 02/19/2014] [Indexed: 06/03/2023]
Abstract
This paper presents a multivariate regression method for the prediction of maltose concentration in aqueous solutions. For this purpose, time and frequency domain of ultrasonic signals are analyzed. It is shown, that the prediction of concentration at different temperatures is possible by using several multivariate regression models for individual temperature points. Combining these models by a linear approximation of each coefficient over temperature results in a unified solution, which takes temperature effects into account. The benefit of the proposed method is the low processing time required for analyzing online signals as well as the non-invasive sensor setup which can be used in pipelines. Also the ultrasonic signal sections used in the presented investigation were extracted out of buffer reflections which remain primarily unaffected by bubble and particle interferences. Model calibration was performed in order to investigate the feasibility of online monitoring in fermentation processes. The temperature range investigated was from 10 °C to 21 °C. This range fits to fermentation processes used in the brewing industry. This paper describes the processing of ultrasonic signals for regression, the model evaluation as well as the input variable selection. The statistical approach used for creating the final prediction solution was partial least squares (PLS) regression validated by cross validation. The overall minimum root mean squared error achieved was 0.64 g/100 g.
Collapse
Affiliation(s)
- D Krause
- Center of Life and Food Sciences Weihenstephan, Group of Bio-Process Analysis, TU Muenchen, Weihenstephaner Steig 20, 85354 Freising, Germany
| | - W B Hussein
- Center of Life and Food Sciences Weihenstephan, Group of Bio-Process Analysis, TU Muenchen, Weihenstephaner Steig 20, 85354 Freising, Germany
| | - M A Hussein
- Center of Life and Food Sciences Weihenstephan, Group of Bio-Process Analysis, TU Muenchen, Weihenstephaner Steig 20, 85354 Freising, Germany.
| | - T Becker
- Center of Life and Food Sciences Weihenstephan, Group of Bio-Process Analysis, TU Muenchen, Weihenstephaner Steig 20, 85354 Freising, Germany
| |
Collapse
|
29
|
Baraliakos X, Kiltz U, Heldmann F, Appel H, Dybowski F, Igelmann M, Kalthoff L, Krause D, Menne HJ, Saracbasi E, Schmitz-Bortz E, Braun J. THU0108 Different Performance of the Major Disease Activity Measures ASDAS and BASDAI in Patients with Axial Spondyloarthritis Treated with Non-Steroidal Anti-Inflammatory Agents (NSAIDS) – Results from A Prospective Study:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.6086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Baraliakos X, Kiltz U, Heldmann F, Appel H, Dybowski F, Igelmann M, Kalthoff L, Krause D, Menne HJ, Saracbasi E, Schmitz-Bortz E, Braun J. SAT0374 Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? A Prospective Study Including Magnetic Resonance Imaging. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.6085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Krause D, Gabriel B, Herborn G, Braun J, Rau R. The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline. Clin Exp Rheumatol 2014; 32:395-400. [PMID: 24773941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2013] [Accepted: 01/09/2014] [Indexed: 06/03/2023]
Abstract
OBJECTIVES Methotrexate (MTX) is the anchor drug in the treatment of patients with rheumatoid arthritis (RA). MTX shows effects on disease activity and mortality. However, it is unclear whether the effect of MTX on mortality depends on its effect on disease activity. METHODS In a post-hoc analysis we analysed the data of our cohort established in Ratingen, Germany, and included all patients starting treatment with MTX (n=271) between 1980 and 1987. One year after baseline (BL), response to MTX treatment was assessed using a modified ACR 20 response. Follow-up data of 250 patients were available after 10 and 18 years. RESULTS After 1 year, there were 66% responders and 20% non-responders; only 14% had discontinued MTX treatment due to side effects or lack of efficacy. Most patients continued MTX treatment irrespective of efficacy. Ten years after BL, 61% of the patients were still treated with MTX. After 18 years, the responder-group showed a standardised mortality ratio of 1.6 compared to 3.2 for the group of non-responders. However, when adjusting for age, gender, response to MTX treatment one year after BL, number of swollen joints and comorbidities after 10 years an independent association of continued MTX treatment with lower mortality was found for the period 10 to 18 years after BL (hazard ratio (HR): 0.63, 95% confidence interval: 0.43-0.92, p=0.015). CONCLUSIONS In this cohort, the mortality lowering effect of continued MTX use was partly independent of its effect on disease activity. This finding may affect treatment decisions concerning RA patients with insufficient response to MTX.
Collapse
Affiliation(s)
- D Krause
- Department of Medical Informatics, Biometry and Epidemiology, Ruhr-University, Bochum, Germany.
| | | | | | | | | |
Collapse
|
32
|
Schirmer M, Zeller J, Krause D, Jekle M, Becker T. In situ monitoring of starch gelatinization with limited water content using confocal laser scanning microscopy. Eur Food Res Technol 2014. [DOI: 10.1007/s00217-014-2213-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Abstract
The pathophysiological mechanism leading to dopaminergic dysfunction in schizophrenia is still unclear. Inflammation seems to play a key role. A dysfunction in the activation of the type 1 immune response is associated with decreased activity of the key enzyme of the tryptophan/kynurenine metabolism, indolamine-2.3-dioxygenase (IDO), results in a higher production of kynurenine acid (KYNA)--an N-methyl-D-aspartate antagonist--in the central nervous system (CNS) and decreased glutamatergic neurotransmission. The differential activation of microglial cells and astrocytes, which serve as immune cells in the CNS, contributes to the TH1-TH2 immune imbalance. Antipsychotics, all acting as dopamine D2 receptor antagonists show several shortcomings. The immune effects of antipsychotics rebalance partly the imbalance of the type-1/type-2 immune response and the overproduction of KYNA. The inflammation is associated with higher prostaglandin E2 (PGE2) production and higher cyclo-oxygenase-2 (COX-2) expression. Increasing evidence from clinical studies with COX-2 inhibitors points to an advantageous effect of anti-inflammatory therapy in schizophrenia, especially in the early stages of the disease. Further options of immunomodulatory therapy in schizophrenia are discussed.
Collapse
Affiliation(s)
- N Müller
- Klinik für Psychiatrie und Psychotherapie, Klinikum der LMU München
| | - D Krause
- Klinik für Psychiatrie und Psychotherapie, Klinikum der LMU München
| | - E Weidinger
- Klinik für Psychiatrie und Psychotherapie, Klinikum der LMU München
| | - M Schwarz
- Institut für Labormedizin, LMU München
| |
Collapse
|
34
|
Kuchheuser W, Fiedler R, Wittig H, Krause D. Forensische Beurteilung einer tödlichen Operationskomplikation Dreidimensionale Darstellung eines Beckens mit künstlichem Hüftgelenk durch Spiral-Computertomographie und Herstellung eines Kunststoffmodells in Originalgröße durch Stereolithographie. Rechtsmedizin (Berl) 2014. [DOI: 10.1007/s00194-002-0155-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Szibor R, Lieske S, Beck N, Krause D. Zur Lokalisation forensisch genutzter Marker im menschlichen Genom Ergebnisse einer world-wide-web-Datenbankrecherche. Rechtsmedizin (Berl) 2014. [DOI: 10.1007/s00194-001-0112-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
|
37
|
Caillot D, Legouge C, Lafon I, Ferrant E, Newinger M, Guido O, Favennec C, Bernard A, Krause D, Martin L, Bonniaud B, Favrot N, Dalle F. Performance du scanner thoracique pour le diagnostic des mucormycoses pulmonaires chez des patients atteints de leucémies aiguës. J Mycol Med 2013. [DOI: 10.1016/j.mycmed.2013.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Haude M, Freitas C, Krause D, Schneider T, Degen H. Innovative Entwicklungen - resorbierbare Scaffolds. Aktuel Kardiol 2013. [DOI: 10.1055/s-0032-1325074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- M. Haude
- Medizinische Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH
| | - C. Freitas
- Medizinische Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH
| | - D. Krause
- Medizinische Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH
| | - T. Schneider
- Medizinische Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH
| | - H. Degen
- Medizinische Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH
| |
Collapse
|
39
|
Baraliakos X, Kiltz U, Heldmann F, Dybowski F, Igelmann M, Kalthoff L, Klink C, Krause D, Saracbasi E, Schmitz-Bortz E, Braun J. SAT0258 A Prospective Evaluation of the Diagnostic Value of Conventional Radiography, Ultrasound and MRI in Comparison to Clinical Examination for the Assessment of Heel and Knee Enthesitis in Patients With Spondyloarthritis and Controls. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Belke-Voss E, Fiehn C, Krause D, Wassenberg S, Rau R. AB0171 Improved radiological outcome of rheumatoid arthritis (ra): evidence for early treatment with methotrexate (mtx) as a key prognostic factor. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Borz E, Floerecke M, Bollow M, Braun J. SAT0283 Living with axial spondyloarthritis: Patients are using different coping strategies:. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
42
|
Vulquin N, Krause D, Crehange G, Martin E, Truc G, Gauthier M, Maingon P, Peignaux-Casasnovas K. MRI Guided Cervical Cancer Brachytherapy: Inter- And Intraobserver Variation in HR-CTV Delineation in T2-weighted and Gadolinium-enhanced T1-weighted Images. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
43
|
Potse M, Krause D, Bacharova L, Krause R, Prinzen FW, Auricchio A. Similarities and differences between electrocardiogram signs of left bundle-branch block and left-ventricular uncoupling. Europace 2012; 14 Suppl 5:v33-v39. [DOI: 10.1093/europace/eus272] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Krause D. Glukokortikoidtherapie in der Rheumatologie - welche Dosis ist optimal? Dtsch Med Wochenschr 2012; 137:1751-4. [DOI: 10.1055/s-0032-1305218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- D. Krause
- Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, und Abteilung für Medizinische Informatik, Biometrie und Epidemiologie, Ruhr-Universität Bochum
| |
Collapse
|
45
|
Vulquin N, Krause D, Créhange G, Martin E, Truc G, Gauthier M, Maingon P, Peignaux-Casasnovas K. Curiethérapie guidée par l’image dans le cancer du col de l’utérus : variations inter- et intraobservateur dans la délinéation du volume cible anatomoclinique à haut risque sur IRM en séquences T2 et T1. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Krause D, Hussein MA, Becker T. Multivariate Online-Überwachung von Bioprozessen. CHEM-ING-TECH 2012. [DOI: 10.1002/cite.201250573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
47
|
Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Flörecke M, Bollow M, Braun J. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 2012; 71:1207-11. [PMID: 22523430 DOI: 10.1136/annrheumdis-2011-200508] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND The threshold for disease activity required to start antitumour necrosis factor (TNF) therapy has been arbitrarily set in patients with axial spondyloarthritis (axSpA) at Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4. How this relates to spinal inflammation is unknown. OBJECTIVE To systematically compare the clinical, laboratory and imaging data of patients with axSpA with respect to their BASDAI level. METHODS A total of 100 consecutive patients with axSpA who had never been treated with TNF blockers were included. Laboratory parameters, spinal MRI and x-rays were quantified. Data were stratified according to BASDAI ≥ 4. RESULTS 44 patients were diagnosed as non-radiographic axSpA (nraxSpA) and 56 patients as ankylosing spondylitis (AS): median age 40.3 ± 10.4 years; 57% male, mean disease duration since diagnosis 6.4 ± 8.4 years, 88% HLA-B27+, mean modified Stokes Ankylosing Spondylitis Spinal Score 8.3 ± 16.4. 60% of patients had spinal inflammation by MRI. The stratification based on BASDAI ≥ 4 disclosed significant differences in most clinical parameters but not for inflammation: patients with nraxSpA and BASDAI < 4 versus ≥ 4 had 0.9 ± 1.4 and 0.5 ± 0.6 inflammatory lesions/patient, respectively (p=0.6), while patients with AS had 3.6 ± 3.7 and 2.7 ± 3.0 inflammatory lesions/patient, respectively (p=0.4). CONCLUSION The burden of inflammation is quite comparable in patients with axSpA-regardless of disease activity. These data clearly challenge the concept of the recommended cut-off point of BASDAI ≥ 4.
Collapse
Affiliation(s)
- U Kiltz
- Department of Rheumatology, Rheumazentrum Ruhrgebiet, St Josefs-Krankenhaus, Landgrafenstr, 15 44652 Herne, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Vleugels K, Schinner S, Krause D, Morawietz H, Bornstein S, Ehrhart-Bornstein M, Krug A. ERK1/2 MAPKs and Wnt Signaling Pathways are Independently Involved in Adipocytokine-Mediated Aldosterone Secretion. Exp Clin Endocrinol Diabetes 2011; 119:644-8. [DOI: 10.1055/s-0031-1284367] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
AbstractObesity is one major risk factor for the development of arterial hypertension, and the development of obesity-related hypertension has been associated with increased plasma aldosterone levels. Our previous work shows a direct stimulatory effect of adipokines on aldosterone secretion from human adrenocortical cells, mediated via ERK1/2-dependent upregulation of steroid acute regulatory protein (StAR) activity. Recent evidence also indicates the involvement of the Wnt-signaling pathway in fat cell-mediated aldosterone secretion. Wnt-signaling molecules are secreted by adipocytes and regulate the activity of SF-1, a key transcription factor in adrenal steroidogenesis. The goal of this study was to investigate the cellular mechanisms of adipocyte-induced aldosterone secretion in detail, and to evaluate effects and possible interactions of the ERK1/2 MAPK- and the Wnt-signaling pathways on adipocyte-induced adrenocortical aldosterone secretion. Our results show that, similar to adipocyte-conditioned medium (ACM), β-catenin, which is an intracellular mediator of canonical Wnt-signaling, induced StAR promotor activity in human NCI-H295R adrenocortical cells, and ACM-induced StAR promotor activity depended on intact SF-1 binding sites. Wnt antagonist sFRP-1 inhibited adipokine-mediated StAR activity, but did not affect ERK1/2 MAPK activation. Accordingly, Wnt did not stimulate ERK1/2 phosphorylation in adrenocortical cells, indicating that ERK1/2 MAPK and Wnt signaling pathways are independently involved in adipocyte-mediated aldosterone secretion.
Collapse
Affiliation(s)
| | - S. Schinner
- Department of Endocrinology, Diabetes and Rheumatology
| | - D. Krause
- Department of Endocrinology, Diabetes and Rheumatology
| | | | | | | | - A. Krug
- Division of Endocrinology, Diabetes, and Hypertension
| |
Collapse
|
49
|
Krause D, Rau R, Braun J. Glucocorticoid treatment in early rheumatoid arthritis. Clin Exp Rheumatol 2011; 29:S121-S125. [PMID: 22018197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2011] [Accepted: 09/14/2011] [Indexed: 05/31/2023]
Abstract
Glucocorticoids (GCs) have been an invaluable tool in the treatment of patients with rheumatoid arthritis (RA) for decades, with a focus mainly on symptom management. In addition, several studies in the last 15 years have shown that GCs are also disease-modifying in patients with RA - which implies that they inhibit radiographic progression. These effects seem to be especially important in the early course of disease. Nonetheless, there is still a lack of knowledge concerning optimal therapeutic strategies with GCs, particularly regarding patient selection and optimal dosage schedules.
Collapse
Affiliation(s)
- D Krause
- Internistische und Rheumatologische Gemeinschaftspraxis, Gladbeck, Germany.
| | | | | |
Collapse
|
50
|
Peignaux-Casasnovas K, Petitfils A, Truc G, Martin E, Chamois J, Ligey A, Crehange G, Khouri C, Maingon P, Krause D. 1078 poster IMAGE GUIDED BRACHYTHERAPY FOR CERVIX CARCINOMA: IMPACT OF MAGNETIC RESONANCE IMAGING. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71200-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|